MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 100880 | Name: Toremifene Citrate
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Toremifene citrate is an oral selective estrogen receptor modulator (SERM) which helps oppose the actions of estrogen in the body. Licensed in the United States under the brand name Fareston, toremifene citrate is FDA-approved for use in advanced (metastatic) breast cancer. It is also being evaluated for prevention of prostate cancer under the brand name Acapodene.

Chemical Structure

Toremifene Citrate
Toremifene Citrate
CAS#89778-27-8 (citrate)

Theoretical Analysis

MedKoo Cat#: 100880

Name: Toremifene Citrate

CAS#: 89778-27-8 (citrate)

Chemical Formula: C32H36ClNO8

Exact Mass: 0.0000

Molecular Weight: 598.09

Elemental Analysis: C, 64.26; H, 6.07; Cl, 5.93; N, 2.34; O, 21.40

Price and Availability

Size Price Availability Quantity
200mg USD 150.00 2 Weeks
500mg USD 250.00 2 Weeks
1g USD 450.00 2 Weeks
2g USD 650.00 2 Weeks
5g USD 950.00 2 Weeks
10g USD 1,650.00 2 Weeks
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
89778-27-8 (citrate) 89778-26-7 (free base)
Synonym
Fareston; FC 1157a; FC-1157a; NK 622; NSC 613680; Toremifene citrate.
IUPAC/Chemical Name
(Z)-2-(4-(4-chloro-1,2-diphenylbut-1-en-1-yl)phenoxy)-N,N-dimethylethan-1-amine 2-hydroxypropane-1,2,3-tricarboxylate
InChi Key
IWEQQRMGNVVKQW-OQKDUQJOSA-N
InChi Code
InChI=1S/C26H28ClNO.C6H8O7/c1-28(2)19-20-29-24-15-13-23(14-16-24)26(22-11-7-4-8-12-22)25(17-18-27)21-9-5-3-6-10-21;7-3(8)1-6(13,5(11)12)2-4(9)10/h3-16H,17-20H2,1-2H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/b26-25-;
SMILES Code
ClCC/C(C1=CC=CC=C1)=C(C2=CC=C(OCCN(C)C)C=C2)\C3=CC=CC=C3.O=C(CC(C(O)=O)(O)CC(O)=O)O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Related CAS# 89778-27-8 (Toremifene Citrate) 89778-26-7 (Toremifene free base)

Preparing Stock Solutions

The following data is based on the product molecular weight 598.09 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Gerken P. Toremifene citrate (Fareston). Clin J Oncol Nurs. 2004 Oct;8(5):529-30. doi: 10.1188/04.CJON.529-530. PMID: 15565747. 2: Vogel CL, Johnston MA, Capers C, Braccia D. Toremifene for breast cancer: a review of 20 years of data. Clin Breast Cancer. 2014 Feb;14(1):1-9. doi: 10.1016/j.clbc.2013.10.014. Epub 2013 Oct 31. PMID: 24439786. 3: Ahola M, Kortesuo P, Kangasniemi I, Kiesvaara J, Yli-Urpo A. In vitro release behavior of toremifene citrate from sol-gel processed sintered silica xerogels. Drug Dev Ind Pharm. 1999 Aug;25(8):955-9. doi: 10.1081/ddc-100102257. PMID: 10434140. 4: Ahola M, Kortesuo P, Kangasniemi I, Kiesvaara J, Yli-Urpo A. Silica xerogel carrier material for controlled release of toremifene citrate. Int J Pharm. 2000 Feb 15;195(1-2):219-27. doi: 10.1016/s0378-5173(99)00403-2. PMID: 10675699. 5: Lu J, Wang X, Xu Y, Dong Y, Yang S, Wu Y, Qin Y, Wu M. Mass spectrometric characterization of toremifene metabolites in human urine by liquid chromatography-tandem mass spectrometry with different scan modes. Analyst. 2011 Feb 7;136(3):467-72. doi: 10.1039/c0an00487a. Epub 2010 Nov 29. PMID: 21113546. 6: Kim HS, Freedland SJ. Androgen deprivation therapy in prostate cancer: anticipated side-effects and their management. Curr Opin Support Palliat Care. 2010 Sep;4(3):147-52. doi: 10.1097/SPC.0b013e32833bd913. PMID: 20592607. 7: Ahola M, Rich J, Kortesuo P, Kiesvaara J, Seppälä J, Yli-Urpo A. In vitro evaluation of biodegradable epsilon-caprolactone-co-D, L-lactide/silica xerogel composites containing toremifene citrate. Int J Pharm. 1999 Apr 30;181(2):181-91. doi: 10.1016/s0378-5173(99)00022-8. PMID: 10370214. 8: Okita A, Saeki T, Aogi K, Osumi S, Takashima S, Okita R, Taira N, Kakishita T, Kurita A. Efficacy and tolerability of weekly paclitaxel in combination with high-dose toremifene citrate in patients with metastatic breast cancer. Acta Med Okayama. 2009 Aug;63(4):187-94. doi: 10.18926/AMO/31816. PMID: 19727203. 9: Shen W, Huang J. Cardiopulmonary resuscitation after video-assisted thoracoscopic surgery with subtotal thyroidectomy: Case report. Int J Surg Case Rep. 2022 Jun;95:107181. doi: 10.1016/j.ijscr.2022.107181. Epub 2022 May 11. PMID: 35661500; PMCID: PMC9163503. 10: Toimela T, Salminen L, Tähti H. Effects of tamoxifen, toremifene and chloroquine on the lysosomal enzymes in cultured retinal pigment epithelial cells. Pharmacol Toxicol. 1998 Dec;83(6):246-51. doi: 10.1111/j.1600-0773.1998.tb01477.x. PMID: 9868742. 11: Shiba E, Watanabe T, Taguchi T, Tsukamoto F, Noguchi S. [Plasma concentrations of toremifene citrate and N-desmethyltoremifene in postmenopausal patients with breast cancer--comparison of 120 mg of toremifene citrate administered once a day and divided into 3 separate doses (t.i.d.)]. Gan To Kagaku Ryoho. 2000 Feb;27(2):245-9. Japanese. PMID: 10700895. 12: Rich J, Kortesuo P, Ahola M, Yli-Urpo A, Kiesvaara J, Seppälä J. Effect of the molecular weight of poly(epsilon-caprolactone-co-DL-lactide) on toremifene citrate release from copolymer/silica xerogel composites. Int J Pharm. 2001 Jan 5;212(1):121-30. doi: 10.1016/s0378-5173(00)00601-3. PMID: 11165827. 13: Miao G, Peng H, Tang H, Liu Y, Zheng X, Liu B, Jiang L, Tang W, He Y, Liu Y, Ren H, Zhao P, Qi Z, Ding C. Antiviral efficacy of selective estrogen receptor modulators against SARS-CoV-2 infection in vitro and in vivo reveals bazedoxifene acetate as an entry inhibitor. J Med Virol. 2022 Oct;94(10):4809-4819. doi: 10.1002/jmv.27951. Epub 2022 Jul 1. PMID: 35733297; PMCID: PMC9350378. 14: Postnikova E, Cong Y, DeWald LE, Dyall J, Yu S, Hart BJ, Zhou H, Gross R, Logue J, Cai Y, Deiuliis N, Michelotti J, Honko AN, Bennett RS, Holbrook MR, Olinger GG, Hensley LE, Jahrling PB. Testing therapeutics in cell-based assays: Factors that influence the apparent potency of drugs. PLoS One. 2018 Mar 22;13(3):e0194880. doi: 10.1371/journal.pone.0194880. PMID: 29566079; PMCID: PMC5864066. 15: Delattin N, De Brucker K, Vandamme K, Meert E, Marchand A, Chaltin P, Cammue BP, Thevissen K. Repurposing as a means to increase the activity of amphotericin B and caspofungin against Candida albicans biofilms. J Antimicrob Chemother. 2014 Apr;69(4):1035-44. doi: 10.1093/jac/dkt449. Epub 2013 Nov 27. PMID: 24284780. 16: Zhang X, Huang B, Du J. Case report: Superficial cervicovaginal myofibroblastoma of the cervix with endometrial carcinoma. Front Med (Lausanne). 2023 Apr 4;10:1160273. doi: 10.3389/fmed.2023.1160273. PMID: 37081843; PMCID: PMC10112509. 17: Taneja SS, Morton R, Barnette G, Sieber P, Hancock ML, Steiner M. Prostate cancer diagnosis among men with isolated high-grade intraepithelial neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral toremifene. J Clin Oncol. 2013 Feb 10;31(5):523-9. doi: 10.1200/JCO.2012.41.7634. Epub 2013 Jan 7. PMID: 23295793. 18: Bansal G, Maddhesia PK, Bansal Y. MS2/TOF and LC-MS/TOF studies on toremifene to characterize its forced degradation products. Analyst. 2011 Dec 21;136(24):5218-28. doi: 10.1039/c1an15587c. Epub 2011 Oct 19. PMID: 22013582. 19: Ogata H, Okamoto Y, Arima Y, Fukushima H, Takeyama H, Yamashita A, Kinoshita M, Suzuki N, Sawada T, Koshida Y, Matsui A, Tachibana A, Nakayama H, Oishi Y, Nogi H, Uchida K. Phase II clinical trial of high-dose toremifene as primary hormone therapy in aromatase inhibitor-resistant breast cancer. Gan To Kagaku Ryoho. 2013 Jun;40(6):749-53. PMID: 23863651. 20: Nomura Y, Tominaga T, Abe O, Izuo M, Ogawa N. [Clinical evaluation of NK 622 (toremifene citrate) in advanced or recurrent breast cancer--a comparative study by a double blind method with tamoxifen]. Gan To Kagaku Ryoho. 1993 Feb;20(2):247-58. Japanese. PMID: 8434963.